Onconic Therapeutics Inc. (KOSDAQ:476060)

South Korea flag South Korea · Delayed Price · Currency is KRW
21,150
+150 (0.71%)
Apr 10, 2026, 3:30 PM KST
Market Cap942.64B +523.6%
Revenue (ttm)53.39B +259.8%
Net Income15.78B
EPSn/a
Shares Out44.89M
PE Ratio59.72
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume235,030
Average Volume634,128
Open21,550
Previous Close21,000
Day's Range20,850 - 21,550
52-Week Range4,993 - 28,900
Betan/a
RSI48.89
Earnings DateMar 20, 2026

About Onconic Therapeutics

Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. The company was founded in 2020 and is based in Seoul, South Kor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 476060
Full Company Profile

Financial Performance

Financial Statements